Russia's Cancer Vaccine Shows 100% Efficacy In Trials; Ready For Use: Report
The Federal Medical and Biological Agency (FMBA), Russia has announced its cancer vaccine has successfully completed trials and is now ready to use. An ambitious leap in oncology and personalized medicine, the world’s first personalized mRNA-based melanoma vaccine will be starting human clinical trials.
FMBA, creators of the Sputnik V COVID-19 vaccine, conducted the research and preclinical trials for the vaccine which reportedly showed safety and high efficacy, according to Veronika Skvortsova, head of the research organization.
Read Also: AI Powered Cancer Vaccine Within Two Days, Says Oracle Chief Larry Ellison
Skvortsova said that the study spanned several years, with the last three dedicated to mandatory preclinical studies, adding that the vaccine is now ready for use. “We are awaiting official approval,” Russian news agency TASS quoted Skvortsova.
The researchers pointed out preclinical results confirmed the vaccine’s safety, even with repeated administration, while observing that reductions in tumor size and slowed tumor progression, ranging from 60% to 80%, depending on the disease characteristics. Studies indicate increased survival rates attributable to the vaccine.
Though the initial target for this vaccine will be colorectal cancer, progress was found developing vaccines for glioblastoma and specific types of melanoma, including ocular melanoma.
